avutometinib,telisotuzumab
verastem,abbvie
['sclc', 'lcsm,(-blcsm)', 'vs-6766', 'nsclc']
 discusses new drugs vs-6766 (raf-mek clamp), her3-dxd (targets her3), &amp; teliso-v (targets met) in treating metastatic #nsclc in 2nd line setting. we need to invest in correlative studies to learn about the biology &amp; serve our patients better #asco22 #lcsm 
LUNGevity Foundation is dedicated to funding lung cancer research and providing support to ALL people affected by lung cancer.